OMS 824

Drug Profile

OMS 824

Alternative Names: OMS-643762; OMS-824

Latest Information Update: 09 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nura
  • Developer Omeros Corporation
  • Class Antipsychotics
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Suspended Schizophrenia

Most Recent Events

  • 16 Mar 2017 Omeros Corporation has patent protection for OMS 824 in USA and ex-US countries
  • 15 Mar 2016 Omeros plans to submit a phase II clinical trial protocol to the US FDA, for the treatment of Schizophrenia (Omeros, Form 10-K, March 2016)
  • 08 Mar 2016 Phase-II development for Huntington's disease and Schizophrenia is ongoing in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top